According to Zhitong Finance App, Xiansheng Pharmaceutical (02096.HK) announced that the Group cooperated with Lingke Pharmaceutical to launch a new drug marketing application for the use of the highly selective second-generation JAK1 inhibitor zeprixitinib for the treatment of moderate to severe active rheumatoid arthritis, which has been officially accepted by the China Drug Administration. This is the second indication for zepcitinib to enter the registration review stage in China after being indicated for severe atopic dermatitis in adults.

Zhitongcaijing · 4d ago
According to Zhitong Finance App, Xiansheng Pharmaceutical (02096.HK) announced that the Group cooperated with Lingke Pharmaceutical to launch a new drug marketing application for the use of the highly selective second-generation JAK1 inhibitor zeprixitinib for the treatment of moderate to severe active rheumatoid arthritis, which has been officially accepted by the China Drug Administration. This is the second indication for zepcitinib to enter the registration review stage in China after being indicated for severe atopic dermatitis in adults.